Senseonics Holdings, Inc. (SENS)

Market Cap	573.91M
Revenue (ttm)	14.83M
Net Income (ttm)	214.99M
Shares Out	478.26M
EPS (ttm)	0.02
PE Ratio	60.00
Forward PE	21.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,755,544
Open	1.21
Previous Close	1.25
Day's Range	1.19 - 1.27
52-Week Range	0.77 - 3.89
Beta	0.88
Analysts	Sell
Price Target	2.07 (+72.5%)
Earnings Date	Feb 27, 2023

About SENS

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serve...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1996
• Employees: 89
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: SENS

Financial Performance

In 2021, SENS's revenue was $13.68 million, an increase of 176.32% compared to the previous year's $4.95 million. Losses were -$302.47 million, 72.7% more than in 2020.

Analyst Forecast

According to 10 analysts, the average rating for SENS stock is "Sell." The 12-month stock price forecast is $2.07, which is an increase of 72.50% from the latest price.

Price Target

$2.07

(72.50% upside)

Analyst Consensus: Sell